
  
    
      
        
        We_PRP are_VBP two_CD of_IN the_DT scientist_NN members_NNS of_IN the_DT President_NNP 's_POS Council_NNP on_IN Bioethics_NNP ._. In_IN late_JJ
        2001_CD ,_, we_PRP were_VBD invited_VBN by_IN the_DT President_NNP of_IN the_DT United_NNP States_NNPS to_TO serve_VB on_IN this_DT Council_NNP ._. The_DT
        Bioethics_NNP Council_NNP was_VBD appointed_VBN by_IN the_DT President_NNP to_TO “ monitor_VB stem-cell_JJ research_NN ,_, to_TO
        recommend_VB appropriate_JJ guidelines_NNS and_CC regulations_NNS ,_, and_CC to_TO consider_VB all_DT of_IN the_DT medical_JJ and_CC
        ethical_JJ ramifications_NNS of_IN biomedical_JJ innovation_NN …_NN ._. This_DT council_NN will_MD keep_VB us_PRP apprised_VBN of_IN new_JJ
        developments_NNS and_CC give_VB our_PRP$ nation_NN a_DT forum_NN to_TO continue_VB to_TO discuss_VB and_CC evaluate_VB these_DT
        important_JJ issues_NNS ._.”
        This_DT was_VBD a_DT difficult_JJ invitation_NN to_TO accept_VB ._. On_IN the_DT one_CD hand_NN ,_, the_DT President_NNP 's_POS views_NNS on_IN the_DT
        use_NN of_IN human_JJ embryonic_JJ stem_NN cell_NN research_NN and_CC somatic_JJ cell_NN nuclear_JJ transfer_NN techniques_NNS were_VBD
        well-known_JJ and_CC in_IN conflict_NN with_IN our_PRP$ own_JJ beliefs_NNS about_IN the_DT costs_NNS and_CC benefits_NNS of_IN the_DT use_NN of_IN
        progressive_JJ technologies_NNS to_TO advance_VB biomedical_JJ research_NN ._. On_IN the_DT other_JJ hand_NN ,_, we_PRP were_VBD
        grateful_JJ that_IN the_DT President_NNP ,_, despite_IN his_PRP$ views_NNS in_IN opposition_NN to_TO these_DT therapies_NNS ,_, was_VBD
        willing_JJ to_TO invite_VB serious_JJ biomedical_JJ scientists_NNS to_TO help_VB formulate_VB advice_NN to_TO him—and_NN
        ultimately_RB to_TO contribute_VB to_TO the_DT development_NN of_IN national_JJ policy—on_NN these_DT critically_RB
        important_JJ advances_NNS ._.
        We_PRP knew_VBD that_IN on_IN this_DT originally_RB 18_CD -_: member_NN (_( but_CC for_IN most_JJS of_IN the_DT past_JJ two_CD years_NNS a_DT
        17_CD -_: member_NN )_) Council_NNP ,_, as_IN scientists_NNS we_PRP would_MD be_VB in_IN the_DT minority_NN in_IN our_PRP$ belief_NN of_IN the_DT good_NN to_TO
        be_VB gained_VBN through_IN these_DT and_CC other_JJ areas_NNS of_IN biomedical_JJ research_NN ._. We_PRP were_VBD also_RB aware_JJ that_IN
        some_DT others_NNS on_IN the_DT Council_NNP had_VBD strong_JJ opposing_VBG views_NNS ._. Thus_RB ,_, it_PRP was_VBD only_RB with_IN the_DT assurances_NNS
        of_IN the_DT Council_NNP chairman_NN ,_, Leon_NNP Kass_NNP of_IN the_DT University_NNP of_IN Chicago_NNP ,_, and_CC of_IN the_DT President_NNP of_IN
        the_DT United_NNP States_NNPS himself_PRP that_IN we_PRP were_VBD persuaded_VBN that_IN our_PRP$ voices_NNS would_MD be_VB heard_VBN and_CC
        integrated_VBN into_IN the_DT statements_NNS of_IN the_DT Council_NNP ._. Furthermore_RB ,_, we_PRP felt_VBD ,_, and_CC continue_VB to_TO feel_VB ,_,
        that_IN bioethical_JJ issues_NNS are_VBP important_JJ not_RB only_RB to_TO all_DT biologists_NNS ,_, but_CC also_RB to_TO society_NN at_IN
        large_JJ ,_, and_CC thus_RB especially_RB worthy_JJ of_IN engaging_VBG debate_NN and_CC discussion_NN ._.
        Two_CD recently_RB issued_VBN reports_NNS of_IN the_DT Council_NNP ,_, “ Beyond_IN Therapy_NNP :_: Biotechnology_NNP and_CC the_DT
        Pursuit_NNP of_IN Happiness_NNP” (_( http_NN :_: /_NN /_NN bioethics_NNS ._. gov_NN /_NN reports_NNS /_NN beyondtherapy_NN /_NN index_NN ._. html_NN )_) and_CC
        “ Monitoring_NN Stem_NNP Cell_NNP Research_NNP” (_( http_NN :_: /_NN /_NN bioethics_NNS ._. gov_NN /_NN reports_NNS /_NN stemcell_NN /_NN index_NN ._. html_NN )_) ,_, are_VBP
        therefore_RB of_IN deep_JJ concern_NN to_TO us_PRP ._. We_PRP discuss_VBP them_PRP in_IN turn_NN below_IN ._.
      
      
        Concerns_NNS about_IN the_DT “ Beyond_IN Therapy_NNP” Report_NNP
        The_DT “ Beyond_IN Therapy_NNP” report_NN deals_NNS with_IN issues_NNS of_IN direct_JJ concern_NN for_IN every_DT thoughtful_JJ
        person_NN ._. However_RB ,_, in_IN the_DT interests_NNS of_IN setting_VBG straight_JJ the_DT record_NN of_IN our_PRP$ views_NNS ,_, as_IN Council_NNP
        members_NNS and_CC scientists_NNS ,_, on_IN the_DT content_NN of_IN this_DT report_NN and_CC for_IN a_DT proper_JJ assessment_NN of_IN the_DT
        scientific_JJ content_NN of_IN the_DT “ Beyond_IN Therapy_NNP” report_NN ,_, we_PRP feel_VBP it_PRP is_VBZ important_JJ to_TO point_VB out_RP
        aspects_NNS of_IN the_DT report_NN for_IN which_WDT we_PRP had_VBD requested_VBN revisions_NNS and_CC for_IN which_WDT those_DT requests_NNS
        were_VBD declined_VBN ._.
        In_IN the_DT discussions_NNS of_IN preimplantation_NN genetic_JJ diagnosis_NN ,_, the_DT specter_NN of_IN designer_NN babies_NNS
        is_VBZ raised_VBN by_IN implying_VBG that_IN selecting_VBG embryos_NNS for_IN intelligence_NN and_CC other_JJ traits_NNS ,_, such_JJ as_IN
        temperament_NN is_VBZ a_DT possibility_NN ._. Scientifically_NNP ,_, this_DT simply_RB is_VBZ highly_RB unlikely_JJ and_CC indeed_RB may_MD
        not_RB even_RB be_VB feasible_JJ ._. While_IN such_JJ scientific_JJ unlikelihood_NN is_VBZ mentioned_VBN in_IN passing_VBG in_IN the_DT
        report_NN ,_, it_PRP is_VBZ easy_JJ to_TO take_VB away_RB from_IN the_DT report_NN the_DT feeling_NN that_IN such_JJ genetic_JJ manipulation_NN
        will_MD happen_VB and_CC is_VBZ even_RB imminent_JJ ._.
        The_DT report_NN also_RB claims_VBZ that_IN “ the_DT underlying_VBG impulse_NN driving_VBG age-retardation_JJ research_NN is_VBZ ,_,
        at_IN least_JJS implicitly_RB ,_, limitless_JJ ,_, the_DT equivalent_NN of_IN a_DT desire_NN for_IN immortality_NN ._.” Furthermore_RB ,_,
        the_DT title_NN of_IN Chapter_NN 4_CD of_IN the_DT report_NN ,_, “ Ageless_NNP Bodies_NNP ,_,” implies_VBZ that_DT immortality_NN is_VBZ the_DT
        goal_NN of_IN this_DT research_NN ,_, despite_IN all_DT reliable_JJ scientific_JJ evidence_NN to_TO the_DT contrary_NN ._. Such_JJ a_DT
        title_NN is_VBZ not_RB consistent_JJ with_IN the_DT knowledge_NN ,_, stated_VBN in_IN that_DT chapter_NN ,_, that_IN there_EX is_VBZ no_DT
        scientific_JJ basis_NN for_IN immortality_NN and_CC implies_VBZ that_IN ,_, by_IN seeking_VBG to_TO maintain_VB and_CC extend_VB
        “ youth_NN ,_,” research_NN into_IN aging_VBG ,_, including_VBG stem_NN cell_NN research_NN ,_, is_VBZ predominantly_RB to_TO serve_VB
        vanity_NN ._. Also_RB ,_, without_IN presenting_VBG scientific_JJ or_CC reliable_JJ evidence_NN ,_, the_DT report_NN presents_VBZ the_DT
        opinion_NN that_DT research_NN into_IN prolonging_VBG healthy_JJ life_NN may_MD result_VB in_IN a_DT lifetime_NN obsession_NN with_IN
        immortality_NN ._. Hence_RB ,_, this_DT chapter_NN in_IN the_DT report_NN falls_VBZ short_JJ of_IN explaining_VBG the_DT serious_JJ
        challenge_NN of_IN preventing_VBG and_CC curing_VBG age-related_JJ disease_NN to_TO extend_VB health—very_NN different_JJ from_IN
        attempting_VBG immortality_NN ._.
        The_DT same_JJ chapter_NN offers_VBZ a_DT sensational_JJ quote_NN from_IN a_DT researcher_NN that_IN “ the_DT real_JJ goal_NN [_NN of_IN
        aging_VBG research_NN ]_NN is_VBZ to_TO keep_VB people_NNS alive_JJ forever_RB ._.” The_DT request_NN that_IN quotes_NNS from_IN researchers_NNS
        more_JJR representative_NN of_IN the_DT biomedical_JJ research_NN community_NN also_RB be_VB included_VBN was_VBD declined_VBN ._.
        This_DT leads_VBZ to_TO a_DT misleading_JJ misrepresentation_NN of_IN the_DT motivation_NN of_IN reputable_JJ researchers_NNS in_IN
        the_DT field_NN of_IN aging_VBG ._.
        In_IN suggesting_VBG that_IN slowing_VBG biological_JJ aging_NN may_MD increase_VB the_DT disjunction_NN between_IN “ social_JJ
        aging_NN” (_( the_DT age_NN at_IN which_WDT children_NNS are_VBP exposed_VBN to_TO “ adult_NN” images_NNS and_CC concepts_NNS )_) and_CC
        “ biological_JJ aging_NN” (_( expected_VBN lifespan_NN )_) ,_, only_RB one_CD view_NN ,_, a_DT conservative_JJ one_CD ,_, of_IN the_DT supposed_VBN
        “ best_JJS” way_NN to_TO raise_VB children_NNS is_VBZ presented_VBN ._. The_DT report_NN also_RB suggests_VBZ ,_, with_IN no_DT clear_JJ
        reasoning_NN behind_IN it_PRP ,_, that_IN longer_JJR lives_NNS will_MD somehow_RB undermine_VB human_JJ determination_NN to_TO
        contribute_VB as_RB much_JJ as_IN one_PRP can_MD during_IN a_DT lifetime_NN ._. Despite_IN requests_NNS for_IN inclusion_NN of_IN material_NN
        that_WDT would_MD allow_VB for_IN a_DT balanced_JJ treatment_NN of_IN these_DT topics_NNS ,_, the_DT report_NN minimized_VBN discussion_NN
        of_IN potential_JJ positive_JJ aspects_NNS of_IN slowing_VBG biological_JJ aging_NN ,_, such_JJ as_IN prolonged_JJ good_JJ
        health_NN ._.
        Finally_RB ,_, the_DT report_NN repeatedly_RB emphasizes_VBZ a_DT “ profound_JJ and_CC mysterious_JJ” link_NN between_IN
        longevity_NN and_CC fertility_NN ,_, thereby_RB leaving_VBG the_DT reader_NN with_IN the_DT distinct_JJ but_CC erroneous_JJ
        impression_NN that_DT anything_NN done_VBN to_TO extend_VB healthy_JJ life_NN will_MD be_VB traded_VBN for_IN decreased_VBD
        fertility_NN ,_, despite_IN the_DT fact_NN that_IN current_JJ scientific_JJ literature_NN ,_, which_WDT was_VBD made_VBN available_JJ
        for_IN inclusion_NN in_IN the_DT report_NN ,_, shows_VBZ a_DT 
        lack_NN of_IN any_DT necessary_JJ 
        mechanistic_JJ linkage_NN of_IN the_DT two_CD ._.
      
      
        Concerns_NNS about_IN the_DT “ Monitoring_NN Stem_NNP Cell_NNP Research_NNP” Report_NNP
        With_IN respect_NN to_TO the_DT “ Monitoring_NN Stem_NNP Cell_NNP Research_NNP” report_NN ,_, we_PRP feel_VBP that_IN some_DT facts_NNS that_WDT
        would_MD help_VB the_DT public_NN and_CC scientists_NNS better_JJR assess_VB the_DT content_NN of_IN the_DT report_NN were_VBD not_RB
        brought_VBN out_IN clearly_RB or_CC were_VBD omitted_VBN entirely_RB ._. First_LS ,_, from_IN the_DT published_VBN scientific_JJ
        literature_NN in_IN peer-reviewed_JJ journals_NNS on_IN stem_NN cells_NNS ,_, a_DT major_JJ message_NN can_MD be_VB distilled_VBN :_:
        namely_RB ,_, the_DT vast_JJ difference_NN that_WDT currently_RB exists_VBZ in_IN our_PRP$ understanding_NN of_IN ,_, and_CC the_DT
        potential_JJ utility_NN of_IN ,_, embryonic_JJ versus_CC adult_NN stem_NN cells_NNS as_IN sources_NNS of_IN material_NN for_IN research_NN
        and_CC clinical_JJ purposes_NNS ._. In_IN brief_JJ ,_, human_JJ stem_NN cells_NNS have_VBP been_VBN isolated_VBN from_IN a_DT variety_NN of_IN
        embryonic_JJ ,_, fetal_JJ ,_, and_CC adult_NN tissue_NN sources_NNS ._. However_RB ,_, enormous_JJ differences_NNS exist_VBP in_IN purity_NN ,_,
        properties_NNS ,_, data_NNS reproducibility_NN ,_, and_CC understanding_NN of_IN cells_NNS from_IN these_DT different_JJ sources_NNS ._.
        Much_JJ of_IN our_PRP$ ignorance_NN is_VBZ related_VBN to_TO the_DT relative_JJ paucity_NN of_IN funding_NN for_IN research_NN using_VBG
        embryonic_JJ stem_NN cells_NNS ._.
        Years_NNS of_IN rigorous_JJ and_CC careful_JJ research_NN in_IN animal_NN models_NNS have_VBP documented_VBN that_IN embryonic_JJ
        stem_NN cells_NNS have_VBP great_JJ utility_NN for_IN scientific_JJ studies_NNS ._. This_DT work_NN has_VBZ also_RB rigorously_RB and_CC
        reproducibly_RB established_VBD the_DT great_JJ plasticity_NN of_IN these_DT cells_NNS and_CC supports_VBZ the_DT opinion_NN that_IN
        human_JJ embryonic_JJ stem_NN cells_NNS possess_VBP the_DT greatest_JJS broadest_JJS potential_NN and_CC promise_NN for_IN clinical_JJ
        applications_NNS ._. As_RB well_RB as_IN therapeutic_JJ uses_NNS ,_, important_JJ potential_JJ applications_NNS include_VBP studies_NNS
        of_IN embryonic_JJ stem_NN cells_NNS bearing_VBG complex_JJ genotypes_NNS susceptible_JJ to_TO poorly_RB understood_VBN common_JJ
        human_JJ diseases_NNS and_CC testing_NN and_CC screening_NN drug_NN efficacy_NN ._.
        The_DT report_NN does_VBZ not_RB make_VB clear_JJ that_IN the_DT best-characterized_JJ adult_NN stem_NN cells_NNS are_VBP
        hematopoietic_JJ stem_NN cells_NNS ._. Currently_RB ,_, major_JJ difficulties_NNS and_CC inadequate_JJ understanding_NN exist_VB
        with_IN most_JJS other_JJ types_NNS of_IN adult_NN stem_NN cells_NNS reported_VBD to_TO date_NN ._. In_IN addition_NN ,_, many_JJ experiments_NNS
        suggesting_VBG that_DT adult_NN stem_NN cells_NNS have_VBP broad_JJ plasticity_NN may_MD be_VB incorrectly_RB interpreted_VBN owing_VBG
        to_TO an_DT error_NN caused_VBN by_IN an_DT experimental_JJ artifact_NN of_IN cell_NN fusion_NN present_JJ in_IN some_DT unknown_JJ
        proportion_NN of_IN the_DT experiments_NNS ._. Research_NNP on_IN some_DT of_IN the_DT reported_VBN adult_NN stem_NN cell_NN
        preparations_NNS may_MD conceivably_RB in_IN the_DT future_JJ demonstrate_VB that_IN they_PRP ,_, too_RB ,_, like_IN hematopoietic_JJ
        stem_NN cells_NNS ,_, can_MD also_RB be_VB prospectively_RB identified_VBN ,_, “ single_JJ cell_NN cloned_VBN ,_,” expanded_VBD
        considerably_RB by_IN growth_NN in_IN vitro_NN with_IN retention_NN of_IN normal_JJ chromosome_NN structure_NN and_CC number_NN ,_,
        and_CC preserved_VBN by_IN freezing_NN and_CC storage_NN at_IN low_JJ temperatures_NNS ._. But_CC it_PRP should_MD be_VB strongly_RB
        cautioned_VBD that_IN this_DT has_VBZ not_RB been_VBN done_VBN for_IN most_JJS adult_NN stem_NN cell_NN preparations_NNS ,_, and_CC ,_, even_RB if_IN
        possible_JJ ,_, it_PRP is_VBZ not_RB clear_JJ that_IN any_DT of_IN the_DT just-mentioned_JJ procedures_NNS will_MD be_VB accomplished_VBN in_IN
        the_DT near_JJ future_JJ ,_, owing_VBG to_TO the_DT technically_RB very_RB demanding_VBG nature_NN of_IN such_JJ experiments_NNS ._.
        We_PRP feel_VBP it_PRP is_VBZ important_JJ to_TO emphasize_VB a_DT point_NN that_IN the_DT report_NN mentioned_VBD ,_, that_IN the_DT
        reported_VBN isolation_NN and_CC properties_NNS of_IN multipotent_NN adult_NN progenitor_NN cells_NNS (_( MAPCs_NNP )_) must_MD be_VB
        reproduced_VBD in_IN additional_JJ laboratories_NNS for_IN any_DT reliable_JJ interpretation_NN of_IN the_DT results_NNS
        reported_VBD with_IN these_DT cells_NNS ._. After_IN considerable_JJ effort_NN ,_, this_DT has_VBZ still_RB not_RB been_VBN achieved_VBN ._.
        Thus_RB ,_, in_IN the_DT reported_VBN results_NNS ,_, the_DT possible_JJ significance_NN of_IN the_DT reported_VBN isolation_NN and_CC
        properties_NNS of_IN human_JJ MAPCs_NNP is_VBZ left_VBN unclear_JJ ,_, as_IN is_VBZ their_PRP$ potential_JJ as_IN a_DT source_NN of_IN stem_NN cells_NNS
        for_IN clinical_JJ purposes_NNS ._. Hence_RB ,_, a_DT strong_JJ overall_JJ caution_NN is_VBZ that_IN many_JJ of_IN the_DT reports_NNS on_IN the_DT
        properties_NNS of_IN cells_NNS differentiated_JJ from_IN adult_NN stem_NN cell_NN preparations_NNS are_VBP to_TO date_NN
        preliminary_JJ and_CC incomplete_JJ ._. If_IN results_NNS with_IN any_DT isolated_VBN and_CC characterized_VBN adult_NN stem_NN cells_NNS
        are_VBP validated_JJ ,_, it_PRP will_MD then_RB be_VB very_RB important_JJ to_TO compare_VB their_PRP$ properties—and_NN those_DT of_IN any_DT
        more_RBR differentiated_JJ cells_NNS that_WDT can_MD be_VB derived_VBN from_IN them—with_NN other_JJ stem_NN cell_NN sources_NNS ,_, such_JJ
        as_IN the_DT well-characterized_JJ hematopoietic_JJ stem_NN cells_NNS ,_, and_CC with_IN human_JJ embryonic_JJ stem_NN cell_NN
        preparations_NNS ._.
        Two_CD major_JJ considerations_NNS argue_VBP strongly_RB for_IN non-commercial_JJ ,_, federal_JJ ,_, peer-reviewed_JJ
        funding_NN to_TO be_VB made_VBN available_JJ for_IN this_DT work_NN ._. The_DT first_JJ is_VBZ the_DT sustained_VBN effort_NN this_DT work_NN
        will_MD require_VB ._. The_DT second_NN is_VBZ the_DT importance_NN of_IN reliable_JJ and_CC unbiased_JJ design_NN of_IN experiments_NNS
        and_CC of_IN open_JJ ,_, public_JJ availability_NN of_IN the_DT complete_JJ findings_NNS ._.
      
      
        Reasons_NNS for_IN Our_PRP$ Concern_NN
        In_IN being_VBG concerned_VBN about_IN the_DT content_NN of_IN these_DT reports_NNS ,_, neither_DT of_IN which_WDT makes_VBZ any_DT
        recommendations_NNS for_IN legislative_JJ or_CC policy_NN actions_NNS ,_, are_VBP we_PRP worrying_VBG too_RB much_JJ ?_. We_PRP think_VBP not_RB ._.
        Indeed_RB ,_, already_RB ,_, sadly_RB as_IN a_DT result_NN of_IN the_DT way_NN the_DT sections_NNS on_IN aging_VBG research_NN in_IN the_DT report_NN
        were_VBD written_VBN ,_, the_DT myth_NN that_DT longevity_NN has_VBZ an_DT inevitable_JJ tradeoff_NN of_IN diminished_VBN fertility_NN is_VBZ
        now_RB gaining_VBG a_DT further_JJ foothold_NN :_: witness_NN the_DT January_NNP 26_CD ,_, 2004_CD ,_, issue_NN of_IN the_DT 
        The_DT New_NNP Republic_NNP ._. In_IN it_PRP ,_, an_DT article_NN about_IN this_DT report_NN of_IN the_DT Council_NNP
        falls_VBZ right_NN into_IN the_DT trap_NN :_: it_PRP states_VBZ ,_, “ But_CC changes_NNS come_VBP with_IN longer_JJR life_NN ._. Worms_NNPS and_CC mice_NNS
        that_WDT are_VBP altered_VBN for_IN extended_VBN lifespans_NNS become_VBP sterile_JJ ,_, or_CC barely_RB reproduce_VB ._.” The_DT public_NN is_VBZ
        done_VBN a_DT disservice_NN when_WRB science_NN is_VBZ presented_VBN incompletely_RB ;_: myths_NNS are_VBP then_RB perpetuated_JJ ._.
        This_DT is_VBZ but_CC one_CD example_NN of_IN the_DT dangers_NNS that_IN three_CD of_IN the_DT Council_NNP members_NNS who_WP are_VBP
        scientists_NNS (_( the_DT two_CD of_IN us_PRP along_IN with_IN Michael_NNP Gazzaniga_NNP of_IN Dartmouth_NNP College_NNP )_) pointed_VBD out_IN ,_,
        in_IN a_DT Commentary_NNP within_IN the_DT edition_NN of_IN the_DT “ Beyond_IN Therapy_NNP” report_NN published_VBN by_IN the_DT Dana_NNP
        Foundation_NNP in_IN November_NNP 2003_CD ._. In_IN that_DT Commentary_NNP ,_, we_PRP stated_VBD that_IN “ Our_PRP$ concern_NN …_NN is_VBZ that_IN ,_,
        moving_VBG forward_RB ,_, the_DT debate_NN carry_NN on_IN with_IN all_DT of_IN the_DT scientific_JJ evidence—or_NN as_RB much_RB as_IN such_JJ
        a_DT widespread_JJ public_JJ discussion_NN can_MD include—and_NN take_VB care_NN not_RB to_TO leave_VB an_DT erroneous_JJ
        impression_NN as_IN to_TO the_DT nature_NN of_IN the_DT potential_JJ problems_NNS at_IN hand_NN ._.” We_PRP ended_VBD the_DT Commentary_NNP by_IN
        saying_VBG “ We_PRP urge_VBP both_DT good_JJ reading_NN and_CC 
        critical_JJ reading_NN !_.” (_( our_PRP$ italics_NNS )_) ._.
        These_DT reports_NNS had_VBD as_IN their_PRP$ premise_NN the_DT aim_NN of_IN neutrality_NN in_IN the_DT scientific_JJ analysis_NN of_IN
        the_DT issues_NNS addressed_VBN ._. But_CC our_PRP$ concern_NN is_VBZ that_IN some_DT of_IN their_PRP$ contents_NNS ,_, as_IN in_IN the_DT few_JJ
        examples_NNS outlined_VBN above_IN ,_, may_MD have_VB ended_VBN up_RP distorting_VBG the_DT potential_NN of_IN biomedical_JJ research_NN
        and_CC the_DT motivation_NN of_IN some_DT of_IN its_PRP$ researchers_NNS ._. Continuing_VBG discussions_NNS will_MD form_VB the_DT basis_NN
        for_IN future_JJ decisions_NNS on_IN these_DT topics_NNS ;_: keeping_VBG such_JJ discussion_NN open_JJ and_CC balanced_JJ is_VBZ of_IN
        paramount_JJ importance_NN ._.
      
      
        
      
    
  
